Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular, Neuroinflammatory, and Oncology Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for P2RY12 (P2Y12 purinergic receptor) drug discovery. As a Class A GPCR critical for platelet activation and microglial chemotaxis, P2RY12 requires full-length, conformationally intact reagents for valid pharmacology. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | P2RY12 Lentivirus Premade Particles (Full-length ORF NM_024536, CMV promoter, Puromycin selection). Also available as Promise-ORF stable cell line essential for GPCR conformation. Sequence Verified. | View P2RY12 Products |
| Antigen | P2RY12 N-Terminal / Extracellular Loops Fusion. High purity (>95%), Endotoxin <1EU/ug. | View P2RY12 Products |
| Benchmark Ab | Anti-P2RY12 Recombinant Antibody. High-affinity positive control, Sequence Verified. | View P2RY12 Products |
| Stable Cell Line | P2RY12/HEK293 Stable Cell Line. High expression (>10⁶ receptors/cell), validated by Calcium Flux, ready for screening. | View P2RY12 Products |
| RNAi Validator | P2RY12 siRNA Set (3 unique targets). Knockdown efficiency >75% at mRNA level. Endotoxin Controlled. | View P2RY12 Products |
| Co-Receptor: P2RY1 | P2RY1 (P2Y1) Lentivirus. Synergistic ADP receptor for dual antiplatelet assays. | View P2RY1 Products |
| Pathway Partner: TBXA2R | TBXA2R (Thromboxane A2 Receptor) Lentivirus. Parallel platelet activation pathway; critical for combination therapy studies. | View TBXA2R Products |
| Off-Target Control: P2RY13 | P2RY13 (P2Y13) Lentivirus. Close homolog (52% identity); essential selectivity counter-screen. | View P2RY13 Products |
| Related Target: F2R (PAR1) | F2R (PAR1) Lentivirus. Thrombin receptor, combination therapy rationale. | View F2R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native GPCR Conformation Integrity | Full-Length Lentiviral Delivery (aa 1-342) with native glycosylation (HEK293 expression). No truncation artifacts. Lentivirus-mediated stable cell lines preserve multipass membrane topology. |
| Gi Coupling Validation | Compatible with cAMP-Inhibition assays (Forskolin-stimulated). High purity (>95%) membrane prep available. Optimal for Calcium Flux/cAMP assays. |
| Receptor Desensitization Studies | Target sequence strictly verified; optimal for Calcium Flux/cAMP assays. |
| Cross-species Translation (Cyno/Mouse) | Human/Mouse/Rat/Cyno ortholog lentiviruses available with species-specific ORF verification. |
| Off-target P2Y13 Selectivity | P2RY13 homolog panel available for counter-screening; sequence divergence verified at TM3/TM7 domains. |
| Lack of Reliable Controls | Recombinant positive control antibodies with strictly controlled endotoxin levels. Validated siRNA available to ensure specific target engagement. |
| False Positives in Screening | Validated siRNA available for receptor-specific signal confirmation in binding studies. |
Live P2RY12 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The P2RY12 therapeutic landscape is expanding beyond acute coronary syndrome (ACS) into neurodegeneration and immuno-oncology. While first-generation irreversible inhibitors (e.g., Clopidogrel) and second-generation reversible inhibitors (Ticagrelor, Prasugrel) have dominated the cardiovascular space, the next R&D wave is targeting optimal safety profiles to mitigate bleeding risks, development of specific reversal agents (antidotes) for emergency interventions, CNS-penetrant inhibitors for microglial modulation in Alzheimer's and Multiple Sclerosis, and anti-tumor metastasis combination therapies. Concurrently, biosimilar competition for ticagrelor is intensifying, driving demand for rapid bioequivalence assays using conformationally accurate full-length receptor systems.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Reversible) | AstraZeneca, Eli Lilly | ACS, Stroke | Rapid Kinetics / Washout (Need live-cell Calcium Flux assays) |
| Small Molecule (Irreversible) | Sanofi, Daiichi Sankyo | Post-PCI Thrombosis | Covalent Binding Confirmation (Need intact full-length protein) |
| Reversal Agents (mAb) | PhaseBio (Bentracimab) | Bleeding Management | Binding Affinity (Need pure target formats) |
| CNS-Penetrant Inhibitor | Biogen, UCB | Alzheimer's, MS | Microglial Migration Assay (Need lentivirus-transduced microglial lines) |
| Targeted Delivery | Emerging Biotechs | Atherosclerosis | Cell-based binding (Need high-expression cells) |
| Antiplatelet Antibody | Phase II Academic | Heparin-Induced Thrombocytopenia | Epitope Mapping vs. ADP-binding pocket (Need mutant panels) |